Scaling Antheia’s Pipeline of Critical Pharmaceutical Ingredients: A Closer Look at Oripavine
Read on for more about how oripavine is used in modern medicine, why this ingredient is vulnerable to supply chain disruptions, and what a modern approach to manufacturing it means for the future of public health.
Can we finally get ahead of drug shortages?

In this episode of Denatured, Christina Smolke, co-founder & CEO at Antheia and Kyle Pudenz, SVP and head of data & AI product at Cencora explore why drug shortages are getting worse, and how combining predictive supply-chain analytics with agile, distributed manufacturing could finally make essential medicines more resilient and accessible.
Brewing the Future of Medicine

From their early days working together at Caltech to building a company that is bringing groundbreaking science into commercial reality, Christina Smolke, Co-Founder & CEO and Kristy Hawkins, Co-Founder & Chief Scientific Officer of Antheia share the remarkable journey behind Antheia.
Antheia lands $80M conditional loan from Trump administration to onshore drug manufacturing

Next-gen manufacturer Antheia is teaming up with the U.S. Department of War to build out its infrastructure and onshore the U.S. drug supply chain.
Antheia Secures $80 Million Conditional Funding Commitment from Department of War’s Office of Strategic Capital
Financing supports Antheia’s domestic manufacturing strategy to onshore critical medicine supply chains MENLO PARK, CA – October 18, 2026 – Antheia, the advanced biosynthesis company delivering 21st-century pharmaceutical manufacturing and innovation, today announced it has received a conditional commitment from the U.S. Department of War’s Office of Strategic Capital (OSC) for a direct, long-term loan […]
Brewing beer, drug ingredients, and making the US supply chain more resilient

Proponents say using fermentation processes can help reduce America’s reliance on China and India for key starting materials and active pharmaceutical ingredients.
Future of Pharma Insights: Q&A with Antheia and TAPI
As global pharma leaders convene in New York City for DCAT Week 2026, Antheia is proud to highlight its strategic partnership with TAPI – Technology and API Services.
Antheia Secures Additional $9 Million in Expanded BioMaP-Consortium Project Agreement to Onshore Pharmaceutical Supply Chains
U.S. government fortifies commitment to advanced manufacturing technology for the domestic production of essential medicines MENLO PARK, Calif., March 4, 2026 – Antheia, the advanced biosynthesis company delivering 21st-century pharmaceutical manufacturing and innovation, today announced it has expanded the scope of its second project agreement with the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), securing an additional $9 million. The additional funds bring the total project investment to $21 […]
Antheia’s 2025 in Review: A Year Of Momentum

As 2025 draws to a close, we’re reflecting on a year defined by momentum. With commercial products to market and a growing ecosystem of partners, we are continuing to realize our vision for a new era of pharmaceutical manufacturing and innovation. Through advanced biosynthesis, we’re transforming how the pharmaceutical industry develops and manufactures the medicines the world needs. […]
Antheia and TAPI Partner to Advance Global Commercialization Strategy for Critical Pharmaceutical Ingredients
New partnership will enable Antheia to increase scale and accelerate time to market for future product launches Menlo Park, Calif. and Parsippany, N.J. – November 20, 2025 – Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, and TAPI – Technology and API Services, today announced a strategic partnership. Antheia will leverage TAPI’s next-generation fermentation capabilities and manufacturing facilities in Europe to further commercialize its pipeline of biosynthetic key starting […]